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Promoting Global Cardiovascular Health
Ensuring Access to Essential Cardiovascular Medicines
in Low- and Middle-Income Countries
Sandeep P. Kishore, MSC,* Rajesh Vedanthan, MD, MPH,† Valentin Fuster, MD, PHD†‡
New York, New York; and Madrid, Spain
On May 13, 2010, a resolution passed at the United Nations for a high-level meeting with heads of state on non-
communicable chronic diseases (NCDs), catapulting NCDs atop the political and health agendas. This meeting
on NCDs, slated for September 2011, provides the rare political moment to commit to scaling up international,
regional, and national efforts to prevent and treat NCDs, giving the issue the priority it deserves. An analogous
high-profile meeting transpired in 2001 on human immunodeficiency virus (HIV)/acquired immune deficiency
syndrome (AIDS), effectively serving as the nucleating event for a vigorous global and political movement to-
wards universal prevention and treatment. As was the case at the HIV/AIDS meeting, a key priority area in the
new NCD movement remains ensuring universal access to reliable, affordable essential medicines to prevent
and treat NCDs. The upcoming meeting, therefore, provides the perfect opportunity to capitalize on the in-
creased political and social awareness of NCDs and to apply the lessons learned from the HIV/antiretroviral ex-
perience in order to improve access to essential medicines for NCDs. Social mobilization and political advocacy,
used in tandem with technical solutions, is an important lesson from the HIV experience, and will likely be im-
portant to ensure access to essential medicines for NCDs, including cardiovascular disease. Here, we use cardio-
vascular disease as a specific case study to examine the issue, outlining early solutions while drawing parallels
and analogies to the HIV experience. (J Am Coll Cardiol 2011;57:1980–7) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.029On May 13, 2010, a resolution passed at the United Nations
for a high-level meeting on noncommunicable chronic
diseases (NCDs), catapulting NCDs atop the political
and health agendas. This meeting on NCDs, slated for
September 2011, provides the rare political moment to
commit to scaling up international, regional, and national
efforts to prevent and treat cardiovascular disease (CVD)
and other NCDs. Currently, there is insufficient political
incentive to control global CVD, reflected in the severe
underfunding of global CVD and related NCDs (1).
Given that CVD is the leading cause of death worldwide,
and that age-standardized CVD mortality is higher in
low- and middle-income countries (LMICs) (2,3), the
global cardiovascular community should take advantage
of this opportunity to marshal the resources required to
control global CVD.
An analogous high-profile meeting transpired in 2001 on
human immunodeficiency virus (HIV)/acquired immune
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2010, accepted December 21, 2010.deficiency syndrome (AIDS), effectively serving as the
nucleating event for a vigorous global and political move-
ment toward universal prevention and treatment. Similar to
the HIV/AIDS experience, a key priority area in the new
global CVD movement remains ensuring universal access to
reliable, affordable essential medicines to prevent and treat
CVD.
Currently, essential CVD medicines have poor availabil-
ity in the public sector in LMICs (4,5). Although there is
better availability of these medicines in the private sector,
the end-user cost makes many medicines unaffordable to the
majority of LMIC populations. In addition, the pharma-
ceutical component of CVD prevention requires daily,
long-term medication treatment, rather than short-course
or 1-time therapy, which increases the lifetime financial
burden. Moreover, given that the vast majority of medicines
are currently purchased through individual out-of-pocket
payments in LMICs (6), the household-level financial
burden is heavy. Differences in local epidemiological CVD
burden, and differences in local practice patterns, can lead to
geographically distinct problems with access to cardiovas-
cular medicines (7). For instance, a 1-month course of
combined therapy for secondary prevention (aspirin, beta-
blocker, angiotensin-converting enzyme inhibitor, and sta-
tin) for patients with established CVD could cost as much
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May 17, 2011:1980–7 Global Access to Cardiovascular Medicinesas 18 days’ wages in Malawi (4). In India, an adult male with
CVD is 20% more likely to have catastrophic spending (when
health care costs capture 40% of a household’s capacity to pay)
and is at 8% greater risk of impoverishment compared with
age-adjusted controls (8). Therefore, it is imperative to ensure
a guaranteed supply of affordable CVD medicines via the
public sector to the majority of LMIC populations at little or
no cost (3).
The path traveled by the HIV/AIDS pioneers over the
past decade to broker increased access to essential life-saving
medicines can serve as a model to do this (9), and given the
current political momentum, should be levered to mobilize
increased global access to drugs for CVD. In 2001, HIV
medications in LMICs rivaled and sometimes exceeded Man-
hattan prices. After a decade of activism and coordinated
efforts by various stakeholders, including political advocacy and
social mobilization by civil society, HIV medications are
increasingly accessible in LMICs, and HIV is increasingly
becoming a chronic disease in parts of the world where it used
to mean an unquestionable and acute death sentence (9). Social
obilization and political advocacy, used with technical solu-
ions, is an important lesson from the HIV experience, and will
e critical to ensure access to essential CVD medicines in
MICs.
Starting Point:
ocial Mobilization and Political Advocacy
he “axis of access” to CVD medicines consists of entities
ncluding multilateral agencies, pharmaceutical companies,
rocurement bodies, local financing and regulatory factors,
nd end users, operating within a social and political
nvironment (Fig. 1). Each component of this axis interacts
ith the other components and with the surrounding
nvironment, thus providing multiple points of intervention
Figure 1 Axis of Access to Cardiovascular Disease Medicines
The “axis of access” to cardiovascular disease medicines consists of entities incl
financing and regulatory factors, and end-users, operating within a social and polit
zation; WTO  World Trade Organization.nd impact. By engaging in po-
itical advocacy and social mobi-
ization, and thereby modifying
he social and political environ-
ent, the axis can be reoriented
oward increasing access to essen-
ial CVD medicines in LMICs.
A key lesson from the HIV
ovement is that access to med-
cines will not become a priority
or particular diseases unless they
ove up on the political, as well as
he health, agendas. The Treat-
ent Action Campaign (TAC), a
outh African group that effec-
ively argued and amplified the
emand for HIV medicines, is a
owerful example of social mobi-
ization leading to political prior-
tization of a disease entity. TAC
rst framed its argument as a hu-
an rights issue, making access to
edicines a fundamental issue of
ocial justice (10). Social mobiliza-
ion was animated by thousands of
atients and citizens draped in
HIV POSITIVE” t-shirts, lively
rotests, and widespread civil dis-
bedience campaigns. TAC’s en-
agement of civil society helped
ead to a comprehensive South African national HIV/AIDS
revention and treatment plan, including access to antiretro-
iral (ARV) medicines in the public sector (11). In light of this
xperience, reframing global CVD in the context of health
Abbreviations
and Acronyms
AIDS  autoimmune
deficiency syndrome
ARV  antiretroviral
CL  compulsory license
CVD  cardiovascular
disease
EML  Essential Medicines
List
FDC  fixed-dose
combination
HIV  human
immunodeficiency virus
LMIC  low- and middle-
income country
NCD  noncommunicable
chronic disease
NEML  national Essential
Medicines List
NGO  nongovernmental
organization
TRIPS  trade-related
aspects of intellectual
property rights
WHO  World Health
Organization
WTO  World Trade
Organization
multilateral agencies, pharmaceutical companies, procurement bodies, local
vironment. NGO  nongovernmental organization; WHO  World Health Organi-uding
ical en
t
c
m
b
n
1982 Kishore et al. JACC Vol. 57, No. 20, 2011
Global Access to Cardiovascular Medicines May 17, 2011:1980–7equity and social justice is an important step to inspire and
energize social mobilization and political advocacy, with the
ultimate goal of improving access to CVD medicines.
WHO Essential Medicines for CVD
Essential medicines are defined by the WHO as medicines
that satisfy the priority health care needs of the population
and are selected with due regard to public health relevance,
evidence on efficacy and safety, and comparative cost effec-
tiveness (12) . The medicines that are considered to be of
highest priority are included on the WHO Model List of
Essential Medicines, or Essential Medicines List (EML).
The EML, first published in 1977 and revised every 2 years by
an expert committee, catalogs critical medicines, and guides
purchasing decisions of governments and many organizations
(12–14). Individual nations align the WHO EML with the
epidemiologic profile and health priorities of their population,
yielding a national essential medicines list (NEML). Medi-
cines on the NEML are subsidized by the public sector (15);
his has helped to reduce the price of antihypertensive medi-
ation in sub-Saharan Africa by over 70% (16). In addition,
edicines on the NEML are the highest priority for coverage
y voluntary or national health insurance programs. In the
ational Mutuelle insurance system in Rwanda, for example,
members are eligible to receive NEML drugs for outpatient
treatment with a 10% copayment (17).
In addition, drugs purchased by major nongovernmental
organizations and the United Nations agencies for donation
are generally limited to those on the EML (12). The EML can
also serve as an advocacy tool. Pressure by HIV treatment and
patient communities, for instance, prompted a special expert
committee meeting that led to the inclusion of the first ARVs
to the EML in 2002 (9). Critically, anyone in the public can
petition the WHO to add or delete a medicine from the EML.
The first EML included nitrates, lidocaine, hydrochlo-
rothiazide, aspirin, and dopamine (Fig. 2). In 1988, epi-
nephrine and sodium nitroprusside were added, followed by
verapamil, digoxin, methyldopa, and streptokinase in the
1990s. In 1997, atenolol was added. Amlodipine, enalapril,
and furosemide were added to the EML in 2003 to 2005
(18). Simvastatin was added in 2007 and amiodarone in
2009. Notably, as of the EML published in 2009, there was
no beta-blocker listed for the heart failure indication. This
fact underscores the need to accelerate EML listing of new
CVD medicines to ensure equitable access to evidence-
based medicines.
Beyond the Model List:
Ensuring Access to Essential Medicines
Although addition to EML is an important step to drawing
attention to drug selection and use by nations, a host of
structural and financial factors still create barriers for LMIC
populations to access essential CVD medicines. Several
approaches, based on the lessons of the HIV experience, and
all currently endorsed by the WHO (13), can help (Fig. 3):1) enhancing capacity for generic substitution; 2) expediting
generic availability by overcoming legal barriers related to
patents and licenses; 3) optimizing local procurement prac-
tices in the public sector; 4) broadening global procurement
via third-party price negotiations; 5) engaging the private
sector to differentially price CVD medicines in LMICs;
6) regulating retail markups in the supply chain; 7) elimi-
nating tariffs on medicines; and 8) developing a fixed-dose
combination (FDC) for CVD (the “Polypill”).
Enhancing capacity for generic substitution. Generics
are more affordable in LMICs, ranging from 3 to 12 times
less expensive than brand-name medicines in the Americas
and the Western Pacific, respectively (5). Thus, substitution
of generic drugs over branded ones is a sensible strategy to
close the treatment gap. But to increase acceptance and use
of low-priced generics, quality must be assured. The WHO
prequalification project completes due diligence on product
manufacturing standards, cataloguing global manufacturers
with safe, reliable, and predominantly generic products for
rapid drug import and use. Manufacturers submit product
dossiers to a WHO committee, that undergo both clinical
and quality assessments, followed by on-site inspection of
the manufacturing plants. The pre-qualification program
has been credited with increasing market penetration by
generic firms and reducing the price of ARVs since 2001
(9). The pre-qualification listing, however, has been limited
to 275 HIV/AIDS, 27 tuberculosis, 17 malaria, and 7
influenza products. The inclusion of CVD products would
immediately strengthen the uptake, procurement, and pa-
tient access to quality generic essential CVD medicines (19).
At the local level, it is critical to promote the uptake of
generics by health professionals and patients alike. Provid-
ing practical incentives, such as fast-tracking regulatory
status approval at the local medicines regulatory authority
for quality generics, can promote dispensing generic CVD
medicines. In addition, cardiology societies in high-income
countries, such as the American College of Cardiology and
the American Heart Association, can work together with
the WHO and regional cardiology societies from LMICs to
jointly develop evidence-based guidelines that encourage
the appropriate use of generic medicines. These guidelines
can guide locally specific and relevant treatment goals and
monitoring outcome measures for simple interventions such
as, for example, use of beta blockers and statins after
myocardial infarction.
Expediting generic availability by overcoming legal barriers
related to patents and licenses. Legal barriers to access,
including patents enforced in LMICs and exclusive licenses,
can thwart generic competition. Countering these legal
barriers can yield substantial reduction in the costs of
essential medicines; generic competition for ARVs re-
duced costs from more than $15,000 per patient-year in
2001 to $87 in 2008 (20). Article 31 of WTO Trade-
Related Aspects Intellectual Property Rights (TRIPS)
legislation features a clause permitting compulsory li-
censes (CLs), which allow for local generic production or
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May 17, 2011:1980–7 Global Access to Cardiovascular Medicinesdrug importation of patented products by non patent
holders (21,22). The interest in CLs for CVD drugs
remains relatively meager in contrast to HIV; to date, the
only CVD drug to receive a CL was clopidogrel in
Thailand, where prices dropped by a reported 90% for
generic versions of the drug (23,24). Other patented
cardiovascular drugs with greater efficacy than generics in
the same class may be good candidates for CLs; however,
achieving this will require more social and political
pressure, as was seen for HIV.
Optimizing local procurement practices in the public
sector. Inefficient procurement practices and management
ave yielded regular stock-outs of medicines, particularly for
VD medicines in the public sector (4,5,16). In Uganda,
here essential medicines are provided free of charge in the
Figure 2 WHO Essential Medicines for Cardiovascular Disease
A timeline of when essential cardiovascular medicines were added to the World H
indications for the medicines (in color) (18). *For pregnancy-induced hypertensionublic sector, availability of atenolol was only 10%, andcaptopril only 20%, and the average length of stock-outs is
nearly 6 months (25). In India, availability of generic
atenolol was 4% and 15% in the states of Karnataka and
West Bengal, respectively (26).
Human resource and geographical constraints, insuffi-
cient funding for training, and poor performance incentives
for supply managers are partly to blame for inefficient supply
chain management. In sub-Saharan Africa, the key lesson
from the HIV experience has been to improve the training
and capacity for supply chain management and maintenance
of buffer stocks of medicines. Currently, the “Stop Stock-
Outs” program has been initiated in which local health
personnel and community volunteers report the availability
of a list of primary care drugs, including atenolol, captopril,
and simvastatin, to the Ministry of Health via Short
rganization (WHO) Essential Medicines List (EML) (starting in 1977) and relevant
*On the Complementary List, for which specialist care is required.ealth O
only. *Message Service (SMS) text (27). Underperforming dis-
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Global Access to Cardiovascular Medicines May 17, 2011:1980–7tricts are supported with supply chain management support
by ministerial and WHO staff. Although promising, no
rigorous data to measure effectiveness of this program are
available yet.
Broadening global procurement via third-party price
negotiations. Third-party price negotiations involve guar-
anteeing increased demand by wholesale purchasers for
medications supplied at lower cost by pharmaceutical com-
panies. These agreements are generally brokered by third
parties (not the consumer or the supplier), such as the
Clinton Foundation (28). As a result, pharmaceutical com-
panies that make generic HIV medications, such as India’s
Cipla, have benefited from greater market information on
drug forecasts, leading to optimal management of produc-
tion risks and more sustainable profits. At the same time, a
consortium of low-income countries is able to access
cheaper medicines for HIV/AIDS patients. The WHO
Figure 3 Summary of Approaches and Specific Solutions to Inc
The 8 key approaches and the specific solutions to increase access to essential c
ACC  American College of Cardiology; AHA  American Heart Association; CVD 
related aspects of intellectual property rights; WHO  World Health Organization.recently reported that third-party price negotiations via the pGlobal Fund to Fight AIDS, Tuberculosis and Malaria
(GFATM) generated the greatest cost-savings over both
differential pricing and pooled purchasing schemes (28).
artly owing to sweeping civil society advocacy, the last
ecade has seen unprecedented investment by large donors
nd procurement agencies, including: the GFATM, the
lobal Alliance for Vaccines and Immunizations, the
lobal Alliance for Improved Nutrition, and the U.S.
resident’s Emergency Plan for AIDS Relief. These agen-
ies can exert significant buying power and negotiate price
iscounts for disease priorities based on large order volumes
nd economies of scale.
Given the benefits demonstrated by third-party price
egotiations for HIV medicines, analogous efforts should be
nitiated for CVD medicines. A coordinated, high-profile
rocurement arm to fight for pooled purchasing for CVD
nd related drugs is now needed. Such a central body could
Access to Essential Cardiovascular Medicines
ascular medicines are displayed. Please see text for full descriptions of each.
iovascular disease; LMIC  low- and middle-income countries; TRIPS  trade-rease
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May 17, 2011:1980–7 Global Access to Cardiovascular Medicinestaneously forecasting regional needs for essential CVD
medicines and coordinating global supply with selected
generic manufacturers. This can only exist with political
prioritization—as was seen for HIV/AIDS.
Engaging the private sector to differentially price CVD
medicines in LMICs. Differential, or tiered pricing, where
drugs are sold at lower prices in LMICs, has historically
been a slow and expensive solution for improving global
access (29). Manufacturers prefer not to offer brand-name
drugs in LMICs at reduced prices for fear of price refer-
encing or parallel re-importation into high-income coun-
tries. Furthermore, when differential pricing has been em-
ployed for HIV medicines, brand-name medicines still cost
more than generics (28). For CVD, branded atenolol in
Uganda is 14 times more expensive and 35% less available
than generic counterparts (25).
However, pharmaceutical firms are now aggressively
looking to LMICs, and their exploding middle class popu-
lations, as potential sources for revenue (30,31). Pfizer (New
York, New York) recently launched atorvastatin (Lipitor) in
Venezuela, offering the branded drug at 30% less cost than
the U.S. price with additional 10% to 20% rebates for the
working poor, yielding a patient cost of $70 to $180 per year
for 40-mg Lipitor (32). In comparison, the global procure-
ment prices on 40-mg generic simvastatin currently ranges
from $25 to $40 per year (33). Although 80% of all
medication expenditures are out of pocket in Venezuela,
Pfizer’s Lipitor has seen success, now accounting for $44
million in sales, up 44% from 2007 (30). These recent
developments will have important implications for access to
medicines in the private sector, where branded drugs are
most often used. Establishing responsible price indicators
for each country or region will be essential for success,
particularly as there is wide variation in per capita incomes
worldwide. The effect on the public sector, where low-cost
generics are most often used, remains to be rigorously
evaluated.
Regulating retail markups in the supply chain. Whole-
sale and retail markups in the private sector also substan-
tially increase the cost of medicines for individuals in
LMICs, which is particularly problematic given the low
availability of CVD medicines in the public sector (4). In
Uganda, retail markups increase the price by over 40% for
medicines in general (25). It is estimated that branded
atenolol purchased in the Ugandan private sector would
impoverish an additional 20% of the population versus just
1% for the lowest-priced generic equivalent (34).
To address the issue of price markups, the government of
Mali effectively fixed maximum end-user prices for whole-
sale and retail purchases in the private sector for over 100
medicines from the NEML. Survey analyses 3 years later
revealed that overall, retail prices had decreased by 22%, and
prices for CVD-specific medicines, such as aspirin and
captopril, had decreased by 11% and 54%, respectively (35).
Critically, the decree did not alter the availability of the
medicines. In Syria, the government has fixed the fees for tthe price components of the medicines (i.e., 20% markup as
profit for manufacturer, 8% markup for marketing, and 8%
wholesale markup; the final dispensing pharmacist’s markup
is applied regressively) (36). On balance, the Syrian solution
yields total retail markups substantially lower than other
comparator regions (e.g., 68% in Lebanon) (37).
Eliminating tariffs on medicines. For CVD medicines,
the cumulative post-manufacture pharmaceutical tariffs on
freight, storage, and distribution of medicines can be as high
as 55% (in India) (38) and are widely known to represent a
regressive form of taxation that unfairly targets the sick. The
tariffs could be eliminated without adverse revenue or
industrial policy impacts (38). Pharmaceutical tariffs gener-
ate 0.1% of gross domestic product in 92% of countries.
Moreover, it has been demonstrated that the economic
losses from tariff reductions can be recovered via economic
gains from a healthier population with greater access to
treatments (15,39). International consensus favors tariff
elimination efforts via the General Agreement on Tariffs
and Trade (40), the Pharmaceutical Tariff Elimination
Agreement (41), and the Doha Declaration (22). Similarly,
the removal of national sales taxes on medicines would
counter the regressive, impoverishing effects of taxation.
Advocacy pressure helped lead to the removal of a standard
10% tax by the East African Community (Kenya, Tanzania,
and Uganda) in March 2005 on any imported pre-packaged
medicines (42). Eliminating tariffs and national sales taxes
for CVD medicines would improve access in LMICs.
Developing a fixed-dose combination for CVD. Multi-
rug regimens, which are a mainstay for the control of major
ommunicable diseases such as tuberculosis, HIV/AIDS,
nd malaria (43), present problems that intensify as the
umber of pills increases: decreased patient adherence,
rescribing and dispensing errors, and increasing cost (44).
he FDC arose as a solution—a proposal to chemically
ncorporate and package a multidrug regimen into single
ill. For communicable diseases in LMICs, FDC has clearly
een shown to increase patient adherence, minimizing
rescribing errors and missed doses by patients while reduc-
ng costs (by as much as 50% in the specific case of the
uberculosis FDC) (44). FDC use simplifies supply chain
anagement while reducing the administrative and logisti-
al burden on procurement officers: forecasting a single pill
ather than several is easier (43). Finally, use of the FDC is
positive force for patient education and counseling
43,44), minimizing patient confusion and simplifying
reatment.
The successful experience with FDC for communicable
iseases portends well for the recent international move-
ent to implement an FDC for CVD prevention (the
Polypill”) using subtherapeutic doses of key drugs (aspirin,
tatin, antihypertensive medication) (45). It has been
hown that multidrug regimens for primary and second-
ry prevention of CVD are cost-effective in all global
egions except sub-Saharan Africa (46). Thus, interest in
he Polypill has increased in recent years, and there are
1986 Kishore et al. JACC Vol. 57, No. 20, 2011
Global Access to Cardiovascular Medicines May 17, 2011:1980–7now several different formulations and combinations in
the process of development and testing (47). If shown to
be effective for primary and secondary prevention of
CVD, the Polypill could become a major public health
action item for the global CVD community (e.g., inclu-
sion on the WHO EML).
Concluding Thoughts:
Highlighting the CVD Treatment Gap
Although one of the Millennium Development Goal targets
is to “provide access to affordable essential drugs in devel-
oping countries” (48,49) and the WHO Secretariat is
committed to “provide support to countries in enhancing
access to essential medicines and affordable medical tech-
nology”(50), the current situation is far from the goal. The
fact that CVD is global in scope but patients face stock-outs
or exorbitant price hikes for basic essential CVD medicines
is fundamentally inequitable.
The upcoming high-level meeting on NCDs can help
move us forward, but requires careful attention to the
importance of social mobilization and political advocacy. In
this article, we have outlined some of the strategies that can
be adopted in order to optimize the axis of access for
essential CVD medicines by learning from the experiences
of HIV/AIDS treatment advocates for ARVs. The success
of robust, patient-centered, human rights–based advocacy
for HIV/AIDS medicines animates the vital role of civil
society in ensuring that all patients are able to access and
afford basic, life-saving essential medicines.
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